|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-28
|
|
pubmed:abstractText |
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biomarkers, Pharmacological,
http://linkedlifedata.com/resource/pubmed/chemical/EGFR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pulmonary Surfactant-Associated...,
http://linkedlifedata.com/resource/pubmed/chemical/Pulmonary Surfactant-Associated...,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
pubmed-author:DoiSeijiS,
pubmed-author:FukudaMinoruM,
pubmed-author:HayashiTomayoshiT,
pubmed-author:KohnoShigeruS,
pubmed-author:NagashimaSeijiS,
pubmed-author:NakamuraYoichiY,
pubmed-author:NakanoHirofumiH,
pubmed-author:NakatomiKatsumiK,
pubmed-author:SodaHiroshiH,
pubmed-author:TakasuMineyoM,
pubmed-author:TakataniHiroshiH,
pubmed-author:TomonagaNanaeN,
pubmed-author:TsukamotoKazuhiroK,
pubmed-author:YamaguchiHiroyukiH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
331-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20401612-Adenocarcinoma,
pubmed-meshheading:20401612-Adult,
pubmed-meshheading:20401612-Aged,
pubmed-meshheading:20401612-Aged, 80 and over,
pubmed-meshheading:20401612-Antineoplastic Agents,
pubmed-meshheading:20401612-Biomarkers, Pharmacological,
pubmed-meshheading:20401612-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20401612-Disease-Free Survival,
pubmed-meshheading:20401612-Female,
pubmed-meshheading:20401612-Humans,
pubmed-meshheading:20401612-Lung Neoplasms,
pubmed-meshheading:20401612-Male,
pubmed-meshheading:20401612-Middle Aged,
pubmed-meshheading:20401612-Polymorphism, Genetic,
pubmed-meshheading:20401612-Prognosis,
pubmed-meshheading:20401612-Protein Kinase Inhibitors,
pubmed-meshheading:20401612-Pulmonary Surfactant-Associated Protein A,
pubmed-meshheading:20401612-Pulmonary Surfactant-Associated Protein D,
pubmed-meshheading:20401612-Quinazolines,
pubmed-meshheading:20401612-Receptor, Epidermal Growth Factor,
pubmed-meshheading:20401612-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
|
|
pubmed:affiliation |
Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
